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Objective: Osteoarthritis is a chronic disease characterized by irreversible damage to joint structures,
including loss of articular cartilage, inﬂammation of the synovial membrane, and alterations in the
subchondral bone. Symptomatic slow-acting drugs for osteoarthritis have been proposed as treatment
because of their excellent safety proﬁle. This review summarizes some data relating to the mechanisms
of action of chondroitin sulfate in the pathophysiology of osteoarthritic joint tissues.
Methods: Peer-reviewed articles obtained using pre-deﬁned search criteria and published in the PubMed
database are summarized. In addition, a relevant in press paper is included.
Results: Chondroitin sulfate belongs to the group of glycosaminoglycans and is a major component of
articular cartilage. The effect of chondroitin sulfate in patients with osteoarthritis is possibly the result of
the stimulation of the synthesis of proteoglycans and the decrease in catabolic activity of chondrocytes
by inhibiting the synthesis of proteolytic enzymes and other factors that contribute to cartilage matrix
damage and cause the death of these cells. Chondroitin sulfate was also shown to exert anti-inﬂam-
matory activity. In addition, it acts on osteoarthritic subchondral bone osteoblasts by modulating the
osteoprotegerin/receptor activator of NF-kB ligand ratio in favor of reduced bone resorption. It is note-
worthy to mention that a head-to-head comparison of the effects of chondroitin sulfate of different
origins and levels of purity on human osteoarthritic cartilage revealed the existence of a disparity in
effects.
Conclusion: The positive effects of chondroitin sulfate on the pathophysiology of osteoarthritis are
possibly due to its contribution to a proper balance between anabolism/catabolism in the articular
tissues.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Osteoarthritis
For decades, it was believed that osteoarthritis consisted only of
the focal destruction of articular cartilage. However, the disease is
now considered a global organ failure involving all of the major
tissues of the joint; namely, the cartilage, synovial membrane, and
subchondral bone1. Emerging evidence suggests that the articular
tissue changes are related to a complex network of biochemical
pathways implicating the diffusion of catabolic factors/mediators
and cytokines between the different joint tissues and the cartilage.
This implies that a molecular cross-talk exists between the synovial
membrane, cartilage, and subchondral bone, which is an integralo: Johanne Martel-Pelletier,
al Hospital Research Centre
St. East, Montreal, Quebec,
2-7582.
elletier).
s Research Society International. Ppart of the disease pathogenesis (Fig. 1). Hence, although destruc-
tion of the articular cartilage characterizes osteoarthritis, inﬂam-
mation of the synovial membrane plays an important role in the
progression of joint tissue lesions. However, there is a general
consensus that synovial inﬂammation is a secondary phenomenon
related tomultiple factors, such as cartilagematrix degradation and
excess amounts of enzymes, nitric oxide and other factors from the
cartilage. In addition, it has been shown that the subchondral bone
is the site of several dynamic morphological changes involving
a remodeling process2. These changes have been found to be
associated with the altered metabolism of osteoblasts.
Chondroitin sulfate
Multiple compounds have been investigated for their positive
effects on clinical symptoms and potential to improve the structural
changes that occur in tissues during osteoarthritis. One of the most
widely used compounds in the management of patients with
osteoarthritis is chondroitin sulfate.ublished by Elsevier Ltd. All rights reserved.
Fig. 1. Representation of the process that occurs in the joint during osteoarthritis. Modiﬁed from Negma, France.
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makes it a biochemical “sister” to hyaluronic acid, dermatan sulfate
and other compounds. Chondroitin sulfate is a long, unbranched
chain made up of a repeating disaccharide structure of glucuronic
acid and N-acetylgalactosamine residues which are used in the
production of proteoglycans [Fig. 2(A)].
In vitro concentrations used for experimentation vs in vivo
availability of chondroitin sulfate in articular tissues
One could question whether the chondroitin sulfate concen-
trations generally used in in vitro studies are attainable in articular
tissues in vivo, as in in vitro studies, a large range of chondroitin
sulfate concentrations have been used (i.e., 12.5e2000 mg/ml) and
most of them employed about 200 mg/ml.
Pharmacokinetic studies performed on humans and experi-
mental animals after oral administration of chondroitin sulfate
revealed that it can be absorbed orally3e8, and a high content of
labeled chondroitin sulfate was found in the synovial ﬂuid and
cartilage4,6. Data also showed that absorbed chondroitin sulfate
reaches the blood compartment as high, intermediate and low
mass derivatives, of which 10% are in the form of chondroitinFig. 2. (A) Chemical structure of chondroitin sulfate and representations of (B) the infrastru
provided by and reproduced with permission from Dr J. Monfort, Hospital del Mar, Universsulfate and 90% in the form of derivatives of lower molecular
weight (disaccharide)8. Moreover, although the in vivo concen-
trations of chondroitin sulfate could be low, the disaccharide
concentrations are high, thus the in vivo effect of chondroitin
sulfate could be the sum of chondroitin sulfate and its disaccha-
ride derivatives. Thus, consequent to the rapid degradation of this
drug to compounds of lower molecular weight as well as the
difﬁculty in differentiating it from the endogenous molecules, it is
very difﬁcult to calculate the Cmax of this drug. It should be noted
that treatment with chondroitin sulfate is characterized by a slow
onset of action, with a maximal clinical effect being attained after
several months (3e6 months) of treatment, which is why the
researchers used such concentrations for in vitro studies.Articular cartilage
In the articular cartilage, aggrecan binds collagen ﬁbrils and
conﬁnes water content [Fig. 2(B and C)]. The high content of
chondroitin sulfate in the aggrecan plays a major role in allowing
cartilage to resist tensile stresses during various loading conditions
by providing the tissue with resistance and elasticity.cture of the cartilage and (C) this tissue’s extracellular matrix components. Generously
itat Autonoma de Barcelona, Barcelona, Spain.
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action of chondroitin sulfate is not limited to the fact that it is part
of the aggrecan; in vivo studies in animal models and in vitro with
human and animal articular cells suggest that the effects of chon-
droitin sulfate result from a combination of numerous factors.
Indeed, in cartilage, chondroitin sulfate was shown to reduce
apoptosis of chondrocytes. This was demonstrated in vivo in an
experimental mouse model of spontaneously developed osteoar-
thritis and in vitro with human and animal chondrocytes9e12.
Moreover chondroitin sulfate was also shown, in vitro, to signiﬁ-
cantly induce the production of proteoglycans13e15. It also reduces
the matrix metalloproteases (MMP), key proteases that are specif-
ically related to articular tissues, including MMP-3, MMP-9,
MMP-13, andMT1-MMP or MMP-1416e19. Other proteases involved
extracellularly that were also decreased by chondroitin sulfate are
cathepsin B and elastase20,21.
Synovial membrane/inﬂammatory factors
Chondroitin sulfate has also shown in vitro anti-inﬂammatory
properties. Indeed, addition of chondroitin sulfate to synoviocytes in
culture during the stationary phase of growth stimulates hyaluro-
nate synthesis, and hyaluronate is suggested to reduce inﬂammation
in articular tissues7,22e24. On bovine articular cartilage explants, this
compound effectively suppresses the interleukin (IL)-1b-induced
inducible nitric oxide synthase (iNOS) cyclooxygenase (COX)-2 and
microsomal prostaglandin E2 synthase (mPGES)-1 gene expression,
as well as IL-1b-induced PGE2 and nitric oxide production9,13,16,25,26.
Interestingly, some of these studies also reported that the combi-
nation of chondroitin and glucosamine sulfate was more effective at
reducing these pro-inﬂammatory factors25,26, and that the combi-
nation can normalize the concentration of these factors16.
Chondroitin sulfate also inhibits several markers of inﬂammation
in vivo in animal models. This was found in two models; the murine
collagen-induced arthritis model (CIA) and the Freund’s adjuvant rat
model of arthritis. In the former model27, chondroitin sulfate
signiﬁcantly reduced some markers of synovitis including cell inﬁl-
tration, ﬁbrosis and proliferation of the synovial lining cells. The IL-6
serum level was also found to be signiﬁcantly reduced28. Moreover,
in this model, in vivo treatment protected against hydrogen peroxide
formation and superoxide anions29e31. In the same line of thought,
various studies have shown that chondroitin-4 sulfate acts as an
antioxidant30,32. In the Freund’s adjuvant rat model of arthritis,
chondroitin sulfate in combination with glucosamine signiﬁcantly
reduced IL-1b levels in joint tissues and serum18.
These above data could possibly explain the clinical results from
the Glucosamine/chondroitin Arthritis Intervention Trial (GAIT)
study33 which evaluated the efﬁcacy and safety of glucosamine and
chondroitin sulfate in the relief of pain in knee osteoarthritis
patients. In this study, chondroitin sulfate or the combination of
glucosamine and chondroitin sulfate did not differ from placebo in
the primary outcome measure. However, one should note that in
the latter study, the placebo response was unusually elevated.
Nonetheless, a subgroup analysis did reveal a signiﬁcant difference
from placebo in the subjects' moderate-to-severe pain treated with
glucosamine plus chondroitin sulfate. In addition, randomization to
chondroitin sulfate was associated with a statistically signiﬁcant
decrease in the incidence of joint swelling, effusion, or both upon
clinical examination, whereas the combination of glucosamine and
chondroitin sulfate was not.
Subchondral bone
In addition to the cartilage and synovial membrane, osteoar-
thritis involves alterations in the subchondral bone metabolism.There is evidence that in this disease the subchondral bone
demonstrates phases of bone resorption and bone formation. In
vivo, indicators of bone remodeling were found to be increased in
osteoarthritis patients34e36. In vitro, recent data demonstrated that
subchondral bone osteoblasts from osteoarthritis patients could be
discriminated into two distinct phenotypes, probably reﬂecting
different metabolic states. Indeed, the data showed that one of the
subpopulations is enriched with factors promoting bone resorp-
tion, while the other has reduced resorptive properties favoring
bone formation37,38.
At present, there is strong evidence that bone remodeling is
tightly regulated by a molecular triad composed of osteoprotegerin
(OPG)/receptor activator of NF-kB (RANK)/RANK ligand (RANKL).
The RANKL (localized on osteoblasts) enhances osteoclastogenesis
via interaction with its receptor RANK (localized on osteoclasts),
whereas OPG (produced by osteoblasts) inhibits this osteoclasto-
genesis by binding to RANKL. Interestingly, although these two
factors, OPG and RANKL, are of key importance in regulating bone
metabolism, the ratio of OPG to RANKL is considered to better
reﬂect environmental signals during joint pathologies than the
levels of each of these factors individually: a high ratio is indicative
of promoting bone formation, while a low ratio favors bone
resorption. Such imbalance has been encountered in some osteo-
lytic lesions where RANKL is upregulated as well as in osteoblastic
disorders where OPG is upregulated.
OPG and RANKL are expressed and modulated in human oste-
oarthritic subchondral bone37. Experiments carried out on each of
the human osteoarthritic subchondral bone osteoblast subpopu-
lations revealed that OPG and RANKL were abnormally expressed
and that the OPG/RANKL ratio was signiﬁcantly reduced in the
subpopulation showing resorptive properties37. Further experi-
ments conducted on this subpopulation of osteoblasts with chon-
droitin and glucosamine sulfate revealed that the presence of
chondroitin sulfate or both chondroitin and glucosamine sulfate
signiﬁcantly upregulated the OPG/RANKL ratio, thus having a direct
effect on curbing the production of OPG and RANKL39. This was
further supported by data showing that the combination of these
compounds decreased the resorptive activity of this osteoblast
subpopulation39. Altogether, these data suggest that chondroitin
sulfate could exert a positive effect on osteoarthritic structural
changes at the subchondral bone level.
Different chondroitin sulfates
Although studies have shown that chondroitin sulfate has
signiﬁcant positive effects on some articular catabolic factors,
caution should be exercised in the study or use of chondroitin
sulfate, as not all are the same or act similarly. Indeed, somemay be
highly efﬁcacious while others may show barely any effect, or even
induce unwanted effects. Our laboratory recently compared chon-
droitin sulfate from three different manufacturers and from
different sources40. In this study, a chondroitin sulfate compound of
porcine origin and two of bovine, each from a different manufac-
turer, were compared for their effects on catabolic and anabolic
factors. Data showed that not all chondroitin sulfates acted simi-
larly, and one even upregulated catabolic factors and decreased
anabolic factors. This illustrates well that not all brands of chon-
droitin sulfate prove to be efﬁcacious.
Conclusion
In conclusion, chondroitin sulfate has been shown tomodify the
chondrocyte death process, to improve the anabolic/catabolic
balance of the extracellular cartilage matrix, to reduce some pro-
inﬂammatory and catabolic factors and, in subchondral bone
J. Martel-Pelletier et al. / Osteoarthritis and Cartilage 18 (2010) S7eS11S10osteoblasts, to increase the ratio of OPG/RANKL, among other
effects. All these ﬁndings provide interesting and insightful infor-
mation about the mechanisms by which chondroitin sulfate and its
combination with glucosamine sulfate may exert the in vivo
beneﬁcial effects on the osteoarthritis disease process as shown in
some clinical trials. For more review details on the human clinical
trials, please refer to the article by Hochberg et al.41 in this
supplement.
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